ArticleRSC advances2020
Polymeric nanoparticles based on carboxymethyl chitosan in combination with painless microneedle therapy systems for enhancing transdermal insulin delivery.
Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 56 citations in OpenAlex.
- Polymeric microneedles for closed-loop drug delivery: from biosensing to therapy.RSC advances · 2026Review
- Development and Characterization of Ginsenoside-Aconitum Lipidic Cubic Nanoparticle-Loaded Dissolving Microneedles for Enhanced Transdermal Anti-inflammatory Therapy.AAPS PharmSciTech · 2026Article
- Current Situation on Diabetes Management: New Weapons Fighting the Disease in 2025.Current drug targets · 2026Review
- Microneedle-nanoparticle hybrid platforms for metabolic syndrome: advances in point-of-care diagnostics and transdermal therapeutics.Discover nano · 2025Review
- Dissolving Microneedle Patch Incorporated with Insulin Nanoparticles for The Management of Type-I Diabetes Mellitus: Formulation Development and in Vivo Monitoring.Advanced pharmaceutical bulletin · 2025Article
- A Bibliometric Analysis of Microneedle-Mediated Drug Delivery: Trends, Hotspots, and Future Directions.Drug design, development and therapy · 2025Review
- Biodegradable polymeric insulin microneedles - a design and materials perspective review.Drug delivery · 2024Review
- Microfluidic-based systems for the management of diabetes.Drug delivery and translational research · 2024Review
- Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity.Pharmaceutics · 2024Review
- Recent Advances in Nanotechnology-Mediated Noninvasive Transdermal and Topical Delivery of Proteins.Small science · 2024Article
- A Comprehensive Review on Prospects of Polymeric Nanoparticles for Treatment of Diabetes Mellitus: Receptors-Ligands,Recent patents on nanotechnology · 2024Review
- Formulation Development of Fast Dissolving Microneedles Loaded with Cubosomes of Febuxostat: In Vitro and In Vivo Evaluation.Pharmaceutics · 2023Article
- Recent Advancements in Microneedle Technology for Multifaceted Biomedical Applications.Pharmaceutics · 2022Review
- Biocompatible nanocarriers for passive transdermal delivery of insulin based on self-adjustingNanoscale advances · 2022Article
- Design and development of insulin microneedles for diabetes treatment.Drug delivery and translational research · 2022Review
- Recent advances in porous microneedles: materials, fabrication, and transdermal applications.Drug delivery and translational research · 2022Review
- Nanocarriers for Skin Applications: Where Do We Stand?Angewandte Chemie (International ed. in English) · 2022Review
- Emergence of microneedles as a potential therapeutics in diabetes mellitus.Environmental science and pollution research international · 2022Review
- Microneedle-Mediated Transdermal Delivery of Drug-Carrying Nanoparticles.Frontiers in bioengineering and biotechnology · 2022Review
- Transdermal Drug Delivery Systems and Their Use in Obesity Treatment.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biodegradable nanoparticles (NPs) have been frequently used as insulin transdermal delivery vehicles due to their grand bioavailability, better encapsulation, controlled release and less toxic properties. However, the skin's barrier properties prevent insulin-loaded NP permeation at useful levels. Nowadays, microneedles have been spotlighted as novel transdermal delivery systems due to their advantages such as painlessness, efficient penetration and no hazardous residues. Herein, we introduce polymeric nanocarriers based on carboxymethyl chitosan (CMCS) for insulin delivery, combining with microneedle therapy systems, which can rapidly deliver insulin (INS) into the skin. The resulting CMCS-based nanocarriers are spherical nanoparticles with a mean size around 200 nm, which could generate supramolecular micelles to effectively encapsulate insulin (EE% = 83.78 ± 3.73%). A nanocrystalline microneedle array (6 × 6, 75/150 μm) was used to penetrate the stratum corneum (SC) for enhancing transdermal insulin delivery, while minimizing the pain sensation caused by intravenous injection. Compared with the transdermal rate of passive diffusion [2.77 ± 0.64 μg (cm
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.